Amundi’s ImmunityBio IBRX Stock Holding History

Amundi’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-16,526	Closed	-$127K	–	2120
2026 Q1	$127K	Buy	+16,526	New	+$113K	﹤0.01%	1944
2023 Q1	–	Sell	-9,454	Closed	-$42K	–	2081
2022 Q4	$42K	Sell	9,454 -17,260	-65%	-$94.8K	﹤0.01%	1726
2022 Q3	$144K	Hold	26,714	–	–	﹤0.01%	1502
2022 Q2	$118K	Buy	+26,714	New	+$107K	﹤0.01%	1420

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Amundi's IBRX Position: Q2 2026 in Review

Amundi sold out of ImmunityBio (IBRX) in Q2 2026, closing a stake of 16,526 shares — an estimated $127K sold.

Amundi first reported a position in IBRX in Q2 2022 and held it in 4 quarters. The position peaked at $144K in Q3 2022. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Amundi reported no remaining ImmunityBio position as of Q2 2026 after selling out during the quarter.
Amundi sold 16,526 ImmunityBio shares in Q2 2026, an estimated $127K.
Amundi first reported a position in ImmunityBio in Q2 2022 and held it in 4 quarters.
Amundi's ImmunityBio position peaked at $144K in Q3 2022.
405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Amundi's 13F filing for Q2 2026, filed 11 Aug 2026.